Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Conditions
Keywords
Phosphodiesterase 5 Inhibitors, BPH/LUTS
Brief summary
At present time several preclinical and clinical study have demonstrated the safety and efficacy of PDE5 (phosphodiesterase type 5)-inhibitors for LUTS/BPH (lower urinary tract symptoms/benign prostatic hyperplasia) patients with or without erectile dysfunction. However, the link between clinical outcomes (symptoms scores), functional activity (urodynamic findings) and molecular pathways, in particular regarding inflammatory pattern (molecular analyses), has not been previously investigated. Aim of present study is to assess, for the first time in literature, changes in pressure flow study (PFS) and changes in molecular profile of prostatic tissue (inflammatory and tissue remodeling markers) in men treated for 12 weeks with tadalafil 5 mg compared with placebo and to correlate these data with changes in symptoms scores (IPSS, International Prostatic Symptoms Score) in men with LUTS secondary to BPH refractory to alpha blockers.
Interventions
DRUGTadalafil
Tadalafil 5 mg once daily for 12 weeks.
OTHERPlacebo
Placebo tablet once daily for 12 weeks.
Sponsors
Eli Lilly and Company
University of Florence
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult male subjects planned to undergo simple prostatectomy (TURP, Transurethral resection of the prostate, or open prostatectomy) for benign prostatic hyperplasia; * treatment with alpha-blockers (Tamsulosin 0.4 mg/die) * being capable of giving informed consent.
Exclusion criteria
* participation in another clinical study; * known or suspected presence of prostatic cancer or PSA (prostate specific antigen) value \>10 ng/mL; * suspected lack of the participant's compliance; * known severe allergies or hypersensitivity to the study drug (active substance or excipients of the formulation); * nown neurogenic bladder (i.e. Parkinson's disease); * suspected or proven urinary infections; * presence of bladder stone.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of LUTS/BPH symptoms | 12 weeks | BPH-associated inflammatory symptoms will be assessed by using the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI). BPH-associated LUTS will be assessed by using International Prostate Symptom Score (IPSS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Volumetric change of the prostate | 12 weeks | Prostate volume as assessed by transrectal ultrasound |
| Change in prostate inhomogeneity and in the number of prostatic macrocalcifications | 12 weeks | BPH-associated prostate inhomogeneity and presence of micro-calcifications will be assessed by using male genital tract male genital tract colour-Doppler ultrasonography. |
| Variation in genic expression of prostatic inflammation markers | 12 weeks | BPH-associated prostate inflammation, fibrosis, and hypoxia will be measured by immunohistochemical and quantitative RT-PCR (qRT-PCR) analyses of inflammatory-, fibrosis- and hypoxia-related markers. |
| Improvement of pressure flow study (PFS) parameters | 12 weeks | Maximum flow rate (Qmax), average flow rate (Qave), voided volume (Vcomp), post void residual volume (PVR) will be evaluated. An abdominal ultrasound immediately after voiding for uroflowmetry will be performed in order to determine the PVR. |
| Improvement in metabolic profile | 12 weeks | Metabolic parameters will be evaluated (glycaemia, insulinemia, total cholesterol, HDL, triglycerides, HbA1c, mean arterial pressure, waist circumference, body mass index) |
| Variation in seminal plasma IL-8 (interleukin-8) levels | 12 weeks | Seminal IL-8, a chemokine involved in male genital tract infection/inflammation, will be evaluated. |
| Improvement in erectile function | 12 weeks | Erectile function will be assessed by using the International Index of Erectile Function-5 (IIEF-5) score. |
| Variation in serum inflammation markers CRP (C-reactive protein) and ESR (Erythrocyte Sedimentation Rate) | 12 weeks | CRP measured on serum and ESR measured on blood drawn at baseline and after 12 weeks |
Countries
Italy
Outcome results
None listed